Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 276 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: chantix Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment

NCT04188106
View directory record Official record
Conditions
Smoking Cessation, Stress, Sleep Disturbance, Nausea
Interventions
Varenicline Pill, Hydroxyzine Pill
Drug
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

PRecision Interventions for SMoking in the SCCS

NCT03521141
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"
Drug · Genetic · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 9, 2026, 10:59 PM EDT
Withdrawn Phase 2 Interventional

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

NCT07171112
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute, Recurrent Acute Pancreatitis, Smoking (Tobacco) Addiction
Interventions
Standard Varenicline Dosing (1 mg BID), Bupropion 150 mg twice daily, Increased Varenicline Dosing (1mg TID)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 9, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

Pre to Postoperative Smoking Cessation

NCT02683161
View directory record Official record
Conditions
Cigarette Smoking, Obesity
Interventions
Varenicline, Contingency Management, Behavioral Counseling
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 9, 2026, 10:59 PM EDT
Active, not recruiting Phase 3 Interventional

Optimizing Tobacco Use Treatment for PLWHA

NCT04176172
View directory record Official record
Conditions
HIV/AIDS, Nicotine Dependence
Interventions
Varenicline, Nicotine patch, Standard treatment, Standard treatment + Managed Problem Solving (MAPS) adherence intervention
Drug · Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Not applicable Interventional

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NCT04694846
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Varenicline on Brain Activity During Nicotine Abstinence

NCT00602927
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Metabolism Informed Smoking Treatment: The MIST RCT

NCT04590404
View directory record Official record
Conditions
Smoking
Interventions
Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach., Nicotine Replacement Therapy, Varenicline, Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)
Behavioral · Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

NCT00455650
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Mecamylamine, Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Varenicline in Ambivalent Smokers

NCT00595868
View directory record Official record
Conditions
Tobacco Use Disorder, Tobacco Use Cessation, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Omaha, Nebraska • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Extended Varenicline Treatment for Smoking Among Cancer Patients

NCT01756885
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers

NCT00781599
View directory record Official record
Conditions
Smokers
Interventions
Chantix, Adherence Counseling, Standard Counseling
Drug · Behavioral
Lead sponsor
Nikki Nollen, PhD, MA
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Sep 9, 2026, 10:59 PM EDT
Not yet recruiting Not applicable Interventional

Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness

NCT07714200
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Cognitive Behavioral Therapy for Smoking Cessation, Nicotine Replacement Therapy, Bupropion, Varenicline, Mobile Contingency Management, Clinic-Based Smoking Cessation Counseling
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cessation Screening Project

NCT04188873
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Preparation Varenicline and Standard Duration Varenicline, Preparation Varenicline and Extended Duration Varenicline, Standard Duration Varenicline, Extended Duration Varenicline, Preparation Combination NRT and Standard Duration Combination NRT, Preparation Combination NRT and Extended Duration Combination NRT, Standard Duration Combination NRT, Extended Duration Combination NRT, Intensive Counseling, Minimal Counseling
Drug · Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Chantix for Treating Cocaine Dependence

NCT00567008
View directory record Official record
Conditions
Cocaine Dependence
Interventions
varenicline, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Pharmacogenetics of Nicotine Addiction Treatment

NCT01314001
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Varenicline, Placebo, Transdermal Nicotine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Buffalo, New York • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Varenicline for Gait and Balance Impairment in Parkinson Disease

NCT01341080
View directory record Official record
Conditions
Parkinson Disease
Interventions
Varenicline, Sugar pill
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Not applicable Interventional

Contingency Management to Promote Smoking Cessation

NCT06456242
View directory record Official record
Conditions
Smoking Cessation
Interventions
CounsCM+MedCM (Health Rewards)
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

UH3 Varenicline for Cannabis Use Disorder

NCT03980561
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Charleston, South Carolina • Pickens, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 4 Interventional Results available

Varenicline for Nicotine Vaping Cessation in Adolescents

NCT05367492
View directory record Official record
Conditions
Vaping, Nicotine Dependence
Interventions
Double Blind Varenicline, Double Blind Placebo, QuitVaping, This Is Quitting
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 25 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders

NCT01000987
View directory record Official record
Conditions
Alcohol Reactivity
Interventions
varenicline, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 9, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Embedding Comprehensive Smoking Cessation Programs Into Community Clinics

NCT04717544
View directory record Official record
Conditions
Smoking Cessation
Interventions
Intervention Arm
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 9, 2026, 10:59 PM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

NCT01170338
View directory record Official record
Conditions
Smoking, Acute Coronary Syndrome
Interventions
Varenicline 100 mg by mouth twice daily, control
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Sep 9, 2026, 10:59 PM EDT